Etrolizumab (rhuMAb Beta7) is a humanized intestinal-selective anti-beta7 integrin monoclonal antibody that selectively blocks the transport and retention of lymphocytes in the intestinal tract for the study of inflammatory bowel disease (IBD).
Purity:
96.60%
CAS Number:
[1044758-60-2]
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted